ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "spondyloarthritis"

  • Abstract Number: 1461 • ACR Convergence 2025

    Digital Behavioral Therapy Improves Outcome in Patients With Axial Spondyloarthritis And Persistent Pain: Results From a Randomized Controlled Trial

    David Kiefer1, Yade Sonkaya2, Dietmar Krause3, Markus Voglau4, Bernhard Mintrop5, Imke Redeker6, Xenofon Baraliakos7 and Uta Kiltz7, 1Ruhr-Universität Bochum; Private practice of rheumatology, Hattingen, Germany, Herne, Germany, 2Ruhr-Universität Bochum, Herne, Germany, 3Elisabeth-Gruppe, Herne, Germany, Essen, Germany, 4myself, Oldenburg, Germany, 5Private rheumatology practice, Hattingen, Germany, 6Ruhr University Bochum, Bochum, Germany, 7Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany

    Background/Purpose: Axial spondyloarthritis (axSpA) is often associated with persistent pain despite effective anti-inflammatory treatment, substantially impacting patients' quality of life. Digital health applications (DiGAs) provide…
  • Abstract Number: 1412 • ACR Convergence 2025

    Classification of sacroiliits using an artificial intelligence model

    Esther Fernández Guill1, Yazmina Bautista Mártir2, Eduardo Fernández Jover3 and Irene Cases Susarte4, 1Sociedad Española de Reumatologia, Murcia, Spain, 2Sociedad Española de Medicina de Familia, Murcia, Spain, 3Universidad Miguel Hernandez, Alicante, Spain, 4Sociedad Española de Radiologia, Murcia, Spain

    Background/Purpose: Axial Spondyloarthritis (axSpA) is a chronic inflammatory disease that mainly involvessacroiliac joints and spine. It is caused by ankylosing spondylitis and other rheumatic diseases…
  • Abstract Number: 0569 • ACR Convergence 2025

    ASAS recommendations on reporting outcomes of core outcome set instruments in axial spondyloarthritis clinical trials

    Floris A. van Gaalen1, Victoria Navarro-Compan2, Xenofon Baraliakos3, Filip Van den Bosch4, Lianne S. Gensler5, Ihsane Hmamouchi6, Robert Landewé7, Pedro Machado8, Helena Marzo-Ortega9, Valeria Rios Rodriguez10, Denis Poddubnyy11, Sofia Ramiro12 and Désirée Van Der Heijde1, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, 3Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 4Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, 5Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 6Health Sciences Research Center (CReSS).Faculty of Medicine, International University of Rabat, Rabat, Morocco, 7Department of Rheumatology, Amsterdam University Medical Center, Amsterdam, Netherlands; and Zuyderland Medical Center, Heerlen, Netherlands, 8Department of Rheumatology, University College London, and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, 9NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom, 10Charité-Universitétsmedizin Berlin, corporate member of Freie universität Berlin and Humboldt-Universität zu Berlin, Department of Gastroenterology, Infectious Diseases and Rheumatology (including Nutrition Medicine), Berlin, Germany, 11Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, 12Leiden University Medical Center, Bunde, Netherlands

    Background/Purpose: The recently updated Assessment of SpondyloArthritis international Society (ASAS) core outcome set (COS)includes an agreed minimum set of instruments that should be used in…
  • Abstract Number: 0535 • ACR Convergence 2025

    Comparing Perspectives of Physician-Assessed and Self-Reported Inflammatory Back Pain: Insights from the SHERPAS Cohort

    Diego Benavent1, Mar Tapia2, Daniel Bernabeu2, Victor Muley2, Manuel Juárez3, Chamaida Plasencia-Rodríguez4, Alejandro Balsa4 and Victoria Navarro-Compan5, 1Hospital Universitari de Bellvitge, Madrid, Spain, 2HU La Paz, Madrid, Spain, 3Rheumatology Unit, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain, 4Hospital Universitario La Paz, MADRID, Spain, 5Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain

    Background/Purpose: Inflammatory back pain (IBP) is very relevant for identifying patients at risk of axial spondyloarthritis (axSpA). Mounting evidence has indicated substantial variability in sensitivity…
  • Abstract Number: 0113 • ACR Convergence 2025

    ZEB2 and MLCK1 may impair gut barrier integrity in MIF-Deficient SKG Mice

    Shaghayegh Foroozan Boroojeni1, Mansi Aparnathi2, Akihiro Nakamura3, Zoya Qaiyum2 and Nigil Haroon4, 1University Health Network/University of Toronto, Toronto, ON, Canada, 2Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, 3Queen's University, Kingston, ON, Canada, 4Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Axial Spondyloarthritis (AxSpA) is a chronic inflammatory condition that primarily affects the musculoskeletal system and has multifactorial origins. The majority of AxSpA patients experience…
  • Abstract Number: 2677 • ACR Convergence 2025

    Quantified Imaging Response at the Sacroiliac Joints to TNF-Inhibitor Therapy in Youth with Axial Disease

    Timothy Brandon1, Rui Xiao2, Daniel Lovell3, Edward Oberle4, Matthew Stoll5, Nancy A. Chauvin6, Michael Francavilla7, Walter P. Maksymowych8 and Pamela Weiss9, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, 3Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Nationwide Children's Hospital, Columbus, OH, 5University of Alabama at Birmingham, Birmingham, AL, 6The Cleveland Clinic, Hummelstown, PA, 7Department of Pediatric Radiology, Children’s Hospital Philadelphia, Philadelphia, PA, 8Department of Medicine, University of Alberta, 568 Heritage Building, Edmonton, AB, Canada, 9Childrens Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: This study assessed the timeline for the resolution of inflammation, changes in structural lesions at the sacroiliac joints (SIJ), and their correlation with patient-reported…
  • Abstract Number: 2336 • ACR Convergence 2025

    Early Axial Spondyloarthritis in Latin America: Prevalence and Regional Differences from the “ESPALDA” Multinational Registry

    Wilson bautista molano1, Guillermo Guaracha2, Fernando Sommerfleck3, Rodrigo García Salinas4, Julio Cesar Casasola Vargas5, John Londono6, Daniel Fernandez7, Diego Vila8, Lorena Brance9, Jossiel Then10, francisco Zeballos11, Lysseth Macias12, Marilu mestanza13, Daisy Sanchez14, lYN chincháy15, Patricia Melgarejo16, Angel Castillo17, Gimena Gomez18, Leandro ferreryra19, Dora candia20, Gustavo medina21, Maria Erguez22, Einer Sanchez4 and Daniel Palleiro23, 1University Hospital Fundacion Santa Fe de Bogota, Bogota, Colombia, 2Instituto Nacional de Ciencias Médicas y Nutrición 'Salvador Zubirán', Ciudad de México, Mexico, Mexico, 3Sanatorio Julio Mendez, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, 4Hospital Italiano La Plata, La Plata, Argentina, 5CAVJ7111038Q9, MEXICO CITY, Mexico, 6Hospital Militar Central , Universidad de La Sabana, Colombia, Bogota, Colombia, 7Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, Colombia; Departamento de Medicina Interna, Unidad de Reumatología, Hospital Universitario San Ignacio, Bogotá, Colombia, BOGOTA, Colombia, 8Hospital Virgen del Carmen, Buenos Aires, Argentina, Buenos Aires, Argentina, 9School of Medicine, Rosario National University, Argentina, Rosario, Argentina, 10HOMS, Santiago, Dominican Republic, 11Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, 12Consultorio sse, Hospital Metropolitano, Ecuador, Quito, Ecuador, 13Hospital Metropolitano, Ecuador, Quito, Ecuador, 14Sociedad Ecuatoriana de Reumatología, GUAYAS - GUAYAQUIL, Ecuador, 15Hospital Guillermo Kaelin de La Fuente, Perú, Lima, Peru, 16Instituto de Previsión Social, Villarrica, Paraguay, 17Centro médico de las Americas, Merida, Mexico, 18Sanatorio Guemes, Buenos Aires, Argentina, 19HIBA, CABA, Ciudad Autonoma de Buenos Aires, Argentina, 20Hospital Regional Primero de Octubre ISSTE, Fuerzas Armadas, México, Durango, Mexico, 21Clinical Hospital Buenos Aires University, Quilmes, Argentina, 22SAR, Guayaquil, Ecuador, 23INRU, Montevideo, Uruguay

    Background/Purpose: The ESPALDA registry, developed by PANLAR, collects data from Latin America to better understand the clinical and epidemiological characteristics of patients with axial spondyloarthritis…
  • Abstract Number: 2156 • ACR Convergence 2025

    Bridging the Gap: Juvenile Spondyloarthritis (JSpA) vs. Chronic Non-Bacterial Osteomyelitis (CNO)

    Sophia Elfrink1, Timothy Brandon1, Jahan Jazayeri1 and Pamela Weiss2, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2Childrens Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: The relationship between juvenile spondyloarthritis (JSpA) and chronic nonbacterial osteomyelitis (CNO) remains poorly defined. This study aimed to assess the proportion of pediatric patients…
  • Abstract Number: 1454 • ACR Convergence 2025

    Long-Term Safety and Tolerability of Bimekizumab Treatment Across Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update from the Phase 3 Studies

    Philip J. Mease1, Denis Poddubnyy2, Rajan Bajracharya3, Barbara Ink3, Myriam Manente4, Luke Peterson5, Katy White6, Peter Nash7 and Lianne S. Gensler8, 1Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, 2Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, 3UCB, Slough, England, United Kingdom, 4UCB, Braine-L'Alleud, Belgium, 5UCB, Morrisville, NC, 6UCB, Slough, United Kingdom, 7School of Medicine, Griffith University, Brisbane, Australia, 8Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA

    Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. Previous analyses of phase (Ph)2b/3 safety data (data…
  • Abstract Number: 1410 • ACR Convergence 2025

    Examining the Interchangeability of Two Different Patient-Reported Global Assessment Measures in an Observational Axial Spondyloarthritis Cohort

    Connor Vershel1, Mark Hwang2, John Reveille3, Seokhun Kim4, Matthew A. Brown5, Michael Weisman6, Mariko Ishimori6 and Michael Ward7, 1Department of Internal Medicine, Division of Rheumatology, John P. and Katherine G. McGovern School of Medicine at the University of Texas Health Science Center at Houston, Houston, TX, 2UTHealth Houston, Houston, TX, 3Department of Medicine, University of Texas Medical Center, Houston, TX, 4UTHealth Houston, Houston, 5Genomics England, London, United Kingdom, 6Cedars-Sinai Medical Center, LOS ANGELES, CA, 7National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, US Department of Health and Human Services, Bethesda, MD

    Background/Purpose: In axial spondyloarthritis cohorts, patient reported outcomes are vital for tracking disease progression and response to therapy. However, many cohorts enrolled prior to the…
  • Abstract Number: 0561 • ACR Convergence 2025

    Patient Characteristics and Treatment Patterns of Traditional and Advanced Therapies Prior to First Secukinumab Intravenous (IV) Administration in Patients with Spondyloarthritis (SpA) in US Real-World Clinical Settings

    Alan Kivitz1, Linda Grinnell-Merrick2, Tim Nguyen2, Ariane Faucher3, Riley Taiji3, Francis Vekeman3 and Atul Singhal4, 1Altoona Center for Clinical Research, Duncansville, PA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, 3STATLOG, Inc, Montreal, QC, Canada, 4SouthWest Arthritis Research Group, Mesquite, TX

    Background/Purpose: Since most approved biologics are administered subcutaneously, there is a need for alternate routes of delivery to treat patients with SpA. Secukinumab is an…
  • Abstract Number: 0533 • ACR Convergence 2025

    Reactive Arthritis Transcriptomics: Enriched Enterobacteriaceae-related Pathways in Synovial Fluid and in Blood is Associated with Drug-free Remission

    Avarna Agarwal1, Phanidhar Dhanekula1, Sarthak Verma1, Subham ravi Nayak2, Prakashini Mruthyanjaya1, Prasanta Padhan1, A Rajkumar Patro2, Ramnath Misra1 and Sakir Ahmed1, 1Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, Bhubaneswar, Orissa, India, 2Department of Microbiology, Kalinga Institute of Medical Sciences, Bhubaneswar, Orissa, India

    Background/Purpose: In reactive arthritis (ReA) approximately a half of patients achieve drug-free remission (DFR), while others develop chronic disease. To identify predictive biomarkers for DFR,…
  • Abstract Number: 0106 • ACR Convergence 2025

    Investigation of DNA Methylation Inhibition in a Mouse Model of Ankylosing Spondylitis

    Goh Murayama1, Kurisu Tada2, Naoto Tamura3, Eri Hayashi1, Taiga Kuga4, Ken Yamaji5 and HOSHIKO FURUSAWA6, 1Department of Internal Medicine and Rheumatology, Juntendo University Graduate School of Medicine, Tokyo, Japan, 2Department of Internal Medicine and Rheumatology, Juntendo University Graduate School of Medicine, Tokyo, 3Juntendo University School of Medicine, Tokyo, Japan, 4Juntendo University, Tokyo, Japan, 5Juntendo University, Department of Internal Medicine and Rheumatology, Tokyo, Japan, 6juntendo, tokyo, Japan

    Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease characterized by enthesitis in axial joints, bone erosion near the entheses, and subsequent irreversible ankylosis due…
  • Abstract Number: 2635 • ACR Convergence 2025

    Differences in structural lesions of the spine between patients with early axSpA and non-axSpA chronic back pain: 2-year results of the SPACE Cohort

    Gizem Ayan1, Liese de Bruin2, Miranda van Lunteren2, Manouk de Hooge3, Ana Bento da Silva2, Mary Lucy Marques4, Monique Reijnierse5, Victoria Navarro-Compan6, Marleen van de sande7, Inger Jorid Berg8, Roberta Ramonda9, Sofia Exarchou10, Désirée Van Der Heijde2, Floris A. van Gaalen2 and Sofia Ramiro11, 1Ankara Research and Training Hospital, Ankara, Turkey, 2Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, 4Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands; and Coimbra Local Health Unit, Coimbra, Portugal, 5Department of Radiology, Leiden University Medical Center, Leiden, Netherlands, 6Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, 7The Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam, Netherlands, 8Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, 9Rheumatology Unit-DIMED-University of Padova ITALY, Padova, Padua, Italy, 10Lund University, Åkarp, Skane Lan, Sweden, 11Leiden University Medical Center, Bunde, Netherlands

    Background/Purpose: The difference in spinal structural lesions and their progression over time between chronic back pain (CBP) patients with and without early axSpA is unknown.…
  • Abstract Number: 2334 • ACR Convergence 2025

    Development and validation analysis of a Corrected Axial Spondyloarthritis Metrology Index

    Dafne capelusnik1, Philip Gardiner2, Elena Nikiphorou3, Désirée Van Der Heijde4, Robert Landewé5, Astrid Van Tubergen6, Annelies Boonen7 and Sofia Ramiro8, 1Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, 2Altnagelvin Hospital, Londonderry, United Kingdom, 3King’s College London, London, United Kingdom, 4Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 5Department of Rheumatology, Amsterdam University Medical Center, Amsterdam, Netherlands; and Zuyderland Medical Center, Heerlen, Netherlands, 6Maastricht university, Maastricht, Netherlands, 7Maastricht University Medical Centre+ & Maastricht University, Maastricht, Limburg, Netherlands, 8Leiden University Medical Center, Bunde, Netherlands

    Background/Purpose: The MOBILITY study, a study on spinal mobility measures in healthy individuals, showed that the Bath Ankylosing Spondylitis Metrology Index (BASMI) often overestimates spinal…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 49
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology